Podcasts about nanopatch

Send us a textProfessor Dr. Mark Kendall (BE PhD FRSA FTSE FNAI) is CEO & Founder of WearOptimo ( https://wearoptimo.com/prof-mark-kendall/ ), a private Australian health-tech company developing the next generation of wearable technology, redefining how we approach hydration and biomarker monitoring.Professor Kendall is also Vice-Chancellor's Entrepreneurial Professor at the Australian National University ( https://research.anu.edu.au/research-initiatives/wearoptimo ).Professor Kendall is a biomedical engineer, inventor, scientist, entrepreneur and business-builder with more than 25 years' experience in creating medical technologies to tackle key global health challenges, and companies licensing/advancing his patents/technologies have created a combined economic value of more than $2 billion for investors.​While at the University of Oxford, Professor Kendall was an inventor of the biolistics technology, commercialized with PowderJect (sold to Chiron Vaccines for US$1 billion in 2003), and then PowderMed, purchased by Pfizer for US$400 million in 2006. Professor Kendall was then Founder, CTO and a Director of Vaxxas (2011-2015), which was the commercialization vehicle for his Nanopatch vaccine delivery invention, featured in his TEDGlobal talk, which has more than 1 million views.In recognition of his innovation and translation of commercial technologies focused on the delivery of drugs to skin, and skin-based disease diagnostics, Professor Kendall has received more than 40 awards and accolades. These include the 2016 CSL Young Florey Medal, a 2012 Rolex Laureate Award for Enterprise and the Eureka Prize for Interdisciplinary Research (2011). He was also named a 2015 World Economic Forum Technology Pioneer, winner of The Australian Innovation Challenge in 2011 and 2004 Younger Engineer of Britain. Professor Kendall's work has featured in diverse media outlets, including TEDGlobal, WIRED, ABC, BBC, NBC, National Geographic, New Scientist, Popular Science and Vanity Fair.Professor Kendall's international recognition extends to his election as a Fellow: of the National Academy of Inventors (NAI, USA); the Royal Society for the encouragement of Arts, Manufactures and Commerce, (RSA, UK); and Australian Academy of Technology and Engineering (ATSE).With a strong global network, and a significant international profile, Professor Kendall serves on the World Economic Forum Global Future Council on Biotechnology and is co-chair of the Australian Stem Cell Therapies Mission.Professor Kendall has a BE (Hons I) and a PhD, Mechanical Engineering from The University of Queensland.#WearOptimo #MarkKendall #WearableBiometrics #HydrationMonitoring #Dehydration #PeakPerformance #EliteAthletes #AgedCare #MarkWebber #CompanionDiagnostics #Theranostics #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

یک فناوری جدید که توسط یک پژوهشگر دانشگاه کوئینزلند ابداع شده است، می تواند تحولی جهانی در زمینه تزریق واکسن ایجاد کند. به گزارش وبسایت دانشگاه کویینزلند، در این روش جدید که نانو پچ (Nanopatch) نامیده می شود، نیازی به استفاده از سوزن و آمپول نیست.

یک فناوری جدید که توسط یک پژوهشگر دانشگاه کوئینزلند ابداع شده است، می تواند تحولی جهانی در زمینه تزریق واکسن ایجاد کند. به گزارش وبسایت دانشگاه کویینزلند، در این روش جدید که نانو پچ (Nanopatch) نامیده می شود، نیازی به استفاده از سوزن و آمپول نیست.

We meet rocket scientist-turned-immunology expert Mark Kendall to find out about his Nanopatch, which could revolutionise vaccinations and eradicate some diseases.

What careers open up for Physics graduates? What if you add a PhD in Chemistry? Meet Sydney University graduate Dr Michelle Deaker talking with Dr Karl about her journey. She started with some entrepreneurial spirit and then added an eye for opportunity. Dr Michelle turns research and ideas into products and then takes them to market. Her Australian venture capital portfolio includes a world-leading vaccine Nanopatch, a watch for tracking dementia patients and a new diagnostic in oncology.  Got a new idea for Dr Michelle ? one-ventures.com.au 

One hundred sixty years after the invention of the needle and syringe, we're still using them to deliver vaccines; it's time to evolve. Biomedical engineer Mark Kendall demos the Nanopatch, a one-centimeter-by-one-centimeter square vaccine that can be applied painlessly to the skin. He shows how this tiny piece of silicon can overcome four major shortcomings of the modern needle and syringe, at a fraction of the cost.

Cento e sessenta anos após a invenção da agulha e da seringa, ainda as utilizamos para aplicar vacinas. É hora de evoluirmos. Mark Kendall, engenheiro biomédico, apresenta o Nanopatch, uma vacina de um centímetro quadrado, que pode ser aplicada à pele, de forma indolor. Ele mostra como esse minúsculo pedaço de silício pode superar quatro grandes pontos fracos das modernas agulha e seringa, por uma fração de seu preço.

Cent soixante ans après l'invention de l'aiguille et de la seringue, nous les utilisons toujours pour administrer les vaccins. Il est temps d'évoluer. L'ingénieur en biomédecine Mark Kendall fait une démonstration du Nanopatch, un vaccin d'une taille d'un centimètre carré qui peut être appliqué sans douleur sur la peau. Il démontre comment ce bout minuscule de silicone peut surpasser les quatre points faibles de l'aiguille moderne et de la seringue, à un prix imbattable.